Emergent BioSolutions (EBS) Research & Development (2011 - 2026)

Emergent BioSolutions' Research & Development history runs 16 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• In Q1 2026, Research & Development fell 30.46% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $48.6 million (down 31.26% YoY), while the FY2025 annual figure was $53.2 million, down 24.75% from the prior year.
• Research & Development was $10.5 million for Q1 2026 at Emergent BioSolutions, down from $12.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $49.8 million in Q2 2022 to a low of $9.1 million in Q4 2024.
• Historically, Research & Development has averaged $25.4 million across 5 years, with a median of $15.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Research & Development slumped 69.05% in 2024, then jumped 32.97% in 2025.
• A 5-year view of Research & Development shows it stood at $47.0 million in 2022, then slumped by 37.45% to $29.4 million in 2023, then plunged by 69.05% to $9.1 million in 2024, then surged by 32.97% to $12.1 million in 2025, then decreased by 13.22% to $10.5 million in 2026.
• The last three Research & Development figures came in at $10.5 million (Q1 2026), $12.1 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.